Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NicVAX for smoking cessation
NCT01102114Phase 3Completed
- Sponsor
- Nabi Biopharmaceuticals
- Start
- Mar 2010
- Primary completion
- Nov 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nicotine dependence comparing NicVAX Vaccine with Placebo Vaccine (2 arms). Primary endpoint: Long Term Abstinence Rate at 1 year. Started Mar 2010; status: completed.
02
Drugs
NicVAX
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT01102114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01102114.